Result of General Meeting

RNS Number : 4731C

Ergomed plc

19 October 2020

 

Ergomed Plc

Result of General Meeting

Guildford, UK - 19 October 2020 : Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that at its General Meeting held today the special resolutions regarding the proposed Capital Reduction were passed with 100% shareholder approval (see table and notes below).

The Capital Reduction remains subject to the Court's approval and a directions hearing is scheduled for 28 October 2020.  If the Court is satisfied that the application should proceed, a second hearing will be held on 10 November 2020 to confirm the Capital Reduction.

A further announcement will be made following the Capital Reduction becoming effective.

Terms used but not defined in this announcement are as defined in the Company's announcement of 1 October 2020.

Details of the voting in respect of each resolution are shown in the table below:

	For		Against		Withheld
Resolution	No. of Shares	%	No. of Shares	%	No. of Shares
1. To cancel the Company's Share Premium Account	41,339,888	100	2,000	0	1,414
2. To capitalise the Company's Merger Reserve by paying up B Shares	41,339,888	100	Nil	0	3,414
3. To cancel the B Shares	41,339,888	100	Nil	0	3,414

Notes:

1.  Votes "For" and "Against" are expressed as a percentage of votes received.

2.  A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

3.  Percentages in relation to Resolution 1 are rounded.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Sue Stuart	[e-mail]
Matthew Neal / Olivia Manser

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com .

 

END

 

 

ROMGCBDGCGBDGGC